| Id: | acc3468 |
| Group: | 2sens |
| Protein: | TBK1 |
| Gene Symbol: | TBK1 |
| Protein Id: | Q9UHD2 |
| Protein Name: | TBK1_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser172 |
| Site Sequence: | ELEDDEQFVSLYGTEEYLHPD |
| Disease Category: | Cancer |
| Disease: | Renal Cancer |
| Disease Subtype: | Clear Cell Renal Cell Carcinoma |
| Disease Cellline: | UMRC2 |
| Disease Info: | |
| Drug: | "TBK1 inhibitors (e.g., CMPD1)" |
| Drug Info: | "TBK1 inhibitors are a class of drugs, with CMPD1 serving as an example within this category." |
| Effect: | modulate |
| Effect Info: | "Phosphorylation at the S172 site of TBK1 protein is upregulated in von Hippel-Lindau (VHL)-deficient clear cell renal cell carcinoma (ccRCC), activating the TBK1 signaling pathway and promoting tumor progression. TBK1 inhibitors (such as CMPD1) can specifically kill VHL-deficient ccRCC cells, suggesting that TBK1 phosphorylation is a potential therapeutic target." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 32127406 |
| Sentence Index: | 32127406_1-2 |
| Sentence: | "The Von Hippel-Lindau gene product is a tumor suppressor whose ubiquitin ligase function is key to oxygen-sensing in cells, whereas Tank-binding kinase (TBK1) is a kinase mostly implicated in innate immune response. The study by Hu and colleagues in this issue reveals that VHL suppresses TBK1 activity under normoxic conditions, and that loss of VHL in kidney cancer cells renders them sensitive to TBK1 inhibition, providing a new potential target for the treatment of clear cell renal cell carcinoma." |
Sequence & Structure:
MQSTSNHLWLLSDILGQGATANVFRGRHKKTGDLFAIKVFNNISFLRPVDVQMREFEVLKKLNHKNIVKLFAIEEETTTRHKVLIMEFCPCGSLYTVLEEPSNAYGLPESEFLIVLRDVVGGMNHLRENGIVHRDIKPGNIMRVIGEDGQSVYKLTDFGAARELEDDEQFVSLYGTEEYLHPDMYERAVLRKDHQKKYGATVDLWSIGVTFYHAATGSLPFRPFEGPRRNKEVMYKIITGKPSGAISGVQKAENGPIDWSGDMPVSCSLSRGLQVLLTPVLANILEADQEKCWGFDQFFAETSDILHRMVIHVFSLQQMTAHKIYIHSYNTATIFHELVYKQTKIISSNQELIYEGRRLVLEPGRLAQHFPKTTEENPIFVVSREPLNTIGLIYEKISLPKVHPRYDLDGDASMAKAITGVVCYACRIASTLLLYQELMRKGIRWLIELIKDDYNETVHKKTEVVITLDFCIRNIEKTVKVYEKLMKINLEAAELGEISDIHTKLLRLSSSQGTIETSLQDIDSRLSPGGSLADAWAHQEGTHPKDRNVEKLQVLLNCMTEIYYQFKKDKAERRLAYNEEQIHKFDKQKLYYHATKAMTHFTDECVKKYEAFLNKSEEWIRKMLHLRKQLLSLTNQCFDIEEEVSKYQEYTNELQETLPQKMFTASSGIKHTMTPIYPSSNTLVEMTLGMKKLKEEMEGVVKELAENNHILERFGSLTMDGGLRNVDCL
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTAC| TBK1-Ser172 | |
|---|---|
| Cancer | Intensity |
| BRCA | 0.272 |
| COAD | |
| HGSC | |
| ccRCC | -0.139 |
| GBM | 0.327 |
| HNSC | |
| LUAD | 1.373 |
| LUSC | -1.976 |
| non_ccRCC | |
| PDAC | 0.062 |
| UCEC | 0.08 |
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
